|
Array Biopharma's asthma drug helps lung function in study
Denver Post Boulder-based Array Biopharma Inc. said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 10.4 percent Tuesday, to close at $6.14 after … Array Seeks Asthma Drug Partner Following Mid-Stage Study Results Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … |
View full post on asthma – Google News